TIANJIN DEV (00882): Tianjin Lisheng Pharmaceutical's net profit attributable to the parent in the first quarter was 55.2753 million yuan, a decrease of 6.56% year-on-year.
Tianjin Development (00882) announced the performance of Li Sheng Pharmaceuticals for the three months ending March 31, 2025, with a total operating income...
TIANJIN DEV (00882) announced the performance of Tianjin Lisheng Pharmaceutical for the three months ending on March 31, 2025. The total operating income was 370 million yuan, an increase of 1.37% year-on-year. The net profit attributable to the owners of the parent company was 55.2753 million yuan, a decrease of 6.56% year-on-year. The basic earnings per share were 0.21 yuan.
Related Articles
KINGSOFT CLOUD (03896): Underwriters have fully exercised their over-allotment option.
On April 24, STANCHART (02888) spent 11.939 million pounds to repurchase 110,620 shares.
ABBISKO-B (02256) spent HKD 758,000 to buy back 100,000 shares on April 25th.
KINGSOFT CLOUD (03896): Underwriters have fully exercised their over-allotment option.
On April 24, STANCHART (02888) spent 11.939 million pounds to repurchase 110,620 shares.
ABBISKO-B (02256) spent HKD 758,000 to buy back 100,000 shares on April 25th.
RECOMMEND
Pan Gongsheng: Will implement a moderately loose monetary policy to promote high-quality development of the Chinese economy.
25/04/2025
Canadian Prime Minister Trudeau: No rush to reach agreement with Trump, US side eventually needs to face reality.
25/04/2025
Alphabet (GOOG.US, GOOGL.US) first quarter revenue and profits exceed expectations, driven by AI and cloud computing performance growth.
25/04/2025
